Key result
New prothrombin F1+2 ELISA detects significant changes in MI, liver disease, leukemia, and anticoagulated patients.
Why the study?
Can a new ELISA assay for prothrombin fragment F1+2 reliably measure coagulation activation processes and monitor anticoagulant therapy?
Observational (n=133)
Yes
Can a new ELISA assay for prothrombin fragment F1+2 reliably measure coagulation activation processes and monitor anticoagulant therapy?
Answers are grounded in this paper and cite their sources.
The new ELISA assay for prothrombin fragment F1+2 is a reliable tool for identifying coagulation activation and monitoring the effects of anticoagulant therapy.
A multicenter study of a recently developed ELISA for the determination of prothrombin fragment F1+2 was performed in order to evaluate analytical and clinical aspects. Mean intra-assay and inter-assay reproducibility were found to be 11.0 and 12.6%, respectively. The measuring range covered by the calibration curve reaches from 0.04 to 10.0 nM/l F1+2. Testing 133 healthy subjects a reference range of 0.37 to 1.11 nM/l F1+2 (2.5-97.5 percentile) with a median of 0.66 nM/l F1+2 was calculated. Minor difficulties with blood sampling (venous occlusion for 2 min) did not affect F1+2 plasma concentrations. Significantly increased F1+2 levels were measured in patients with leukemia (p < 0.0001), severe liver disease (p < 0.005) and after myocardial infarction (p < 0.01). Elevated F1+2 concentration before the beginning of heparin therapy (1.25 nM/l) decreased to 0.77 nM/l (p < 0.0001) after 1 day of therapy. For patients in the stable phase of oral anticoagulant therapy decreasing F1+2 concentrations were measured with increasing INR. F1+2 levels were already significantly reduced in patients with INR < 2.0 (0.56 nM/l; p = 0.0005). Thus F1+2 determination may be helpful in identifying activation processes as well as in monitoring anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Bruhn et al. (1992) conducted an observational in Healthy subjects and patients with leukemia, liver disease, myocardial infarction, or on anticoagulants (n=133). ELISA for prothrombin fragment F1+2 determination was evaluated on Prothrombin fragment F1+2 concentration. A new ELISA for prothrombin fragment F1+2 established a reference range of 0.37-1.11 nM/l and detected significant changes in patients with leukemia, liver disease, MI, and on anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: